Board Meeting Details

The meeting was held on May 26, 2026, commencing at 02:10 pm and ending at 03:35 pm.

Financial Results Overview

Audited Financial Results for FY Ended March 31, 2026 (in lakhs):

  • Revenue from operations: ₹1,407.97 crore
  • Other income: ₹17.34 crore
  • Total income: ₹1,425.31 crore
  • Total expenses: ₹975.45 crore
  • Profit before tax: ₹449.86 crore
  • Tax expense: ₹122.95 crore
  • Net profit for the year: ₹326.91 crore
  • Other comprehensive income: ₹(0.28) crore
  • Total comprehensive income: ₹326.63 crore

Quarter Ended March 31, 2026 (in lakhs):

  • Revenue from operations: ₹370.45 crore
  • Other income: ₹4.00 crore
  • Total income: ₹374.45 crore
  • Total expenses: ₹241.24 crore
  • Profit before tax: ₹133.21 crore
  • Tax expense: ₹38.61 crore
  • Net profit for the quarter: ₹94.60 crore

Dividend Recommendation

The Board recommended a final dividend of ₹45 per equity share (face value ₹10 each) for FY ended March 31, 2026, aggregating to ₹747.00 lakhs. The dividend will be paid on or before September 25, 2026, subject to shareholder approval at the ensuing 59th Annual General Meeting.

Total dividend for the financial year (including interim dividend and one-time special dividend of ₹160 per equity share declared on February 6, 2026) is ₹205 per equity share.

Capital Structure

Paid-up equity share capital remains unchanged at ₹16.60 crore (face value ₹10 per share).

Key Financial Metrics

  • Basic and diluted EPS for FY26: ₹196.94
  • Basic and diluted EPS for Q4 FY26: ₹56.99
  • Other equity: ₹507.95 crore as of March 31, 2026

Comparability Note

The Board changed the financial year end from June 30 to March 31 effective January 23, 2025. Accordingly, the previous financial year (2024-25) covered only 9 months from July 1, 2024 to March 31, 2025, making figures not comparable with the current year.

Segment Information

The company identified Pharmaceuticals as its single primary reportable segment under Ind AS 108.

Labour Code Impact Assessment

The Company evaluated the impact of the four Labour Codes effective from November 21, 2025, and assessed that the incremental impact is not material as the current salary structure is in line with requirements.

Subsidiaries and Associates

The Company does not have any subsidiary, associate, or joint venture as of March 31, 2026.

Assets and Liabilities (as at March 31, 2026)

  • Total assets: ₹841.35 crore
  • Total equity: ₹524.55 crore
  • Non-current liabilities: ₹61.87 crore
  • Current liabilities: ₹254.93 crore

Cash Flow Statement (FY Ended March 31, 2026)

  • Net cash from operating activities: ₹337.79 crore
  • Net cash from investing activities: ₹(5.65) crore
  • Net cash used in financing activities: ₹(343.92) crore
  • Net decrease in cash: ₹(4.87) crore
  • Cash and cash equivalents at year-end: ₹177.40 crore

Auditor Confirmation

Haribhakti & Co. LLP, Chartered Accountants (Firm Registration No. 103523W/W100048), issued an unmodified opinion on the financial results.

Availability of Results

The audited financial results are available on the company website (www.pghealthindia.com) and on BSE and NSE websites.